Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAStem cells
- Development stage
- Phase 2
- Lead developer
- Beijing Zehui Chenxing Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intraarticular
01
Overview
CAStem cells (also known as IMRCs or M cells) are a cell replacement therapy consisting of immunity- and matrix-regulatory cells differentiated from human embryonic stem cells (hESCs). Developed by Beijing Zehui Chenxing Biotechnology in collaboration with the Institute of Zoology, Chinese Academy of Sciences, these cells possess potent immunomodulatory and anti-fibrotic properties. They are designed to modulate the immune system and regulate extracellular matrix production, showing higher expression of genes related to proliferation and tissue repair compared to traditional umbilical cord mesenchymal stem cells. CAStem is currently being investigated in clinical trials for various inflammatory and fibrotic conditions, including acute graft-versus-host disease, interstitial lung diseases, ARDS, and COVID-19-related pulmonary complications.
- Brand names
- CAStem
- Other names
- CAStem cell injectionhuman embryonic stem cell-derived M cellshESC-derived IMRCsMSC-like cell therapy
Beyond the preview
Go deeper on CAStem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAStem cells.